CORT
CORT clinical trials: CORCEPT THERAPEUTICS INC
Every trial on ClinicalTrials.gov where CORCEPT THERAPEUTICS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 80
- Trials linked
- 73
- As lead sponsor
- 7
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
CORT on the catalyst calendar · CORT registry changes
- Primary completion Dec 2027Sponsor estimatePhase 2NCT06906341Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersCorcept Therapeutics · Ovarian CancerRecruitingCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03604198Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeCorcept Therapeutics · Cushing SyndromeActive, not recruitingCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2026ActualPhase 1NCT07553663Evaluating the Pharmacokinetics and Safety of MiricorilantCorcept Therapeutics · Nonalcoholic Steatohepatitis (NASH)CompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 13, 2026ActualPhase 1NCT06947304Evaluation of Miricorilant on Liver Fat in Patients With MASLDCorcept Therapeutics · Nonalcoholic Steatohepatitis (NASH)CompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 13, 2026ActualPhase 2NCT06108219A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated...Corcept Therapeutics · Nonalcoholic Steatohepatitis (NASH)CompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2025ActualPhase 3NCT05257408Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or...Corcept Therapeutics · Ovarian NeoplasmActive, not recruitingCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 2NCT07259317Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaCorcept Therapeutics · AdenocarcinomaRecruitingCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 2NCT05407324Dazucorilant in Patients With Amyotrophic Lateral SclerosisCorcept Therapeutics · Amyotrophic Lateral SclerosisActive, not recruitingCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 1/Phase 2NCT07276373Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesCorcept Therapeutics · NeoplasmsRecruitingCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2021ActualPhase 1/Phase 2NCT03437941Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerCorcept Therapeutics · Metastatic Castration-Resistant Prostate CancerTerminatedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 3, 2026ActualPhase 1NCT07240116Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult SubjectsCorcept Therapeutics · HealthyCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2025ActualNo phase registeredNCT06829537Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)Corcept Therapeutics · Resistant HypertensionCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 16, 2021ActualPhase 2NCT03776812Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or...Corcept Therapeutics · Recurrent Ovarian CancerCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2024ActualPhase 3NCT04308590A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasCorcept Therapeutics · HypercortisolismCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2, 2024ActualPhase 1NCT06495944Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult ParticipantsCorcept Therapeutics · Healthy AdultsCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2024ActualPhase 3NCT03697109A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCorcept Therapeutics · Cushing SyndromeCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2024ActualPhase 1NCT06928779Effects of Hepatic Impairment on the Pharmacokinetics of DazucorilantCorcept Therapeutics · Hepatic ImpairmentCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2024ActualPhase 1NCT05553470Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantCorcept Therapeutics · Non-alcoholic Steatohepatitis (NASH)CompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2024ActualPhase 4NCT05772169Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)Corcept Therapeutics · HypercortisolismCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2022ActualPhase 2NCT03818256A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar...Corcept Therapeutics · Antipsychotic-induced Weight Gain (AIWG)CompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 18, 2023ActualNo phase registeredNCT05320146A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic...Corcept Therapeutics · Nonalcoholic Steatohepatitis (NASH)CompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2024ActualPhase 1NCT05117489A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)Corcept Therapeutics · Nonalcoholic Steatohepatitis (NASH)CompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2022ActualPhase 2NCT04524403A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking...Corcept Therapeutics · Antipsychotic-induced Weight Gain (AIWG)CompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 17, 2023ActualPhase 1NCT04373265Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress...Corcept Therapeutics · Adrenocortical CarcinomaCompletedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 23, 2021ActualPhase 3NCT04329949Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaCorcept Therapeutics · Metastatic Pancreatic Ductal AdenocarcinomaTerminatedCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 55 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner